First Trust NYSE Arca Biotechnology ETF opened trading today at $26.26 and closed at $26.26. prices ranged from a low of $26.26 to a high of $26.26.

The price boosted 5.55% from the previous day's close of $24.88.

Today across North America, the TSX Composite closed 0.14% at 20958.44, the S&P 500 closed -0.28% at 4769.83, the Dow Jones Industrial Average closed -0.05% at 37689.54 and the Nasdaq Composite closed -0.56% at 15011.35.

First Trust NYSE Arca Biotechnology ETF traded under FBT on the Toronto Stock Exchange (TSX).

A total of 450 shares was traded during the session, with total trades of 3. On average, First Trust NYSE Arca Biotechnology ETF has traded 802 shares over the last 5-days and 1,251 year-to-date.

The TSX market on the whole today saw 1,296 price advancers against 3,915 declines and 127 unchanged.

During the prior 52 weeks, FBT.TO has traded as high as $27.72 (February 06,2023) and low as $23.22 (October 27,2023). Moreover, the shares have decreased -2.01% in the last 52 weeks, while they have advanced 1.27% since the start of 2024.

Following today's trading, First Trust NYSE Arca Biotechnology ETF has a market capitalization of $0.00 on a float of 0 shares outstanding. Its annual EPS is $None.

First Trust NYSE Arca Biotechnology ETF is a None company headquartered in, None.

The First Trust NYSE Arca Biotechnology ETF seeks to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE Arca Biotechnology Index. *On February 2021, the First Trust AlphaDEX U.S. Materials Sector Index ETF changed its investment objectives to seek to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE Arca Biotechnology Index..

Currently, First Trust NYSE Arca Biotechnology ETF has an average recommendation of "Strong Sell" based on 0.00 analysts according to Zacks. Currently, there are for the stock.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..